NuCana BioMed is an emerging biopharmaceutical company dedicated to the discovery, development and commercialisation of innovative, rationally designed medicines that address significant unmet medical needs. Our management team has extensive experience of building successful biopharmaceutical companies. This includes the formation and subsequent growth of Bioenvision into a NASDAQ National listed, global biopharmaceutical company, which was acquired by Genzyme Corporation in October 2007. Specific management expertise includes the development, approval and commercialisation of oncology medicines. We are developing a portfolio of first-in-class and best-in-class pharmaceutical products designed to treat life-threatening or debilitating diseases. Our primary focus is in the area of oncology, although our technology platform has broader clinical potential.

Founded in 2008, Qurient takes a pioneering position in the newly emerging biotech industry in Korea. Qurient introduced a unique virtual biotech model, running R&D operations not only in clinical development phases, but also in early discovery research stage, named ‘Network R&D’ model. Network R&D aims to capital efficient innovation, being able to tackle on new scientific innovations in various therapeutic areas through experts network.

Engages in research of medical therapies for diseases

Andes Biotechnologies is a leading nucleic acid-based drug discovery and development company focused on solid tumor cancers. The Company has discovered two novel families of long non-coding RNAs: sense (S-RNA) and antisense (AS-RNA). Both are present in all human cells, are synthesized in the mitochondria and migrate to the nucleus. The proprietary technology developed by Andes Biotechnologies is based on oligonucleotide drugs that target the novel long non-coding regulatory RNAs in tumor cells inducing apoptosis. Andes Biotechnologies has an active investigational new drug (IND) application in the United States and is currently engaged in the clinical development of its lead drug Andes-1537. Andes Biotechnologies is supported by a proven and experienced management team, a robust network of key national and international collaborators in the cancer field, and has an extensive intellectual property portfolio. Andes Biotechnologies was founded in 2008 and is located in Santiago, Chile.

Enzon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development, manufacturing, and commercialization of important medicines for patients with cancer and other life-threatening conditions. Enzon has a portfolio of four marketed products, ONCASPAR®, DEPOCYT®, ABELCET® and ADAGEN®. The Company's drug development programs utilize several cutting-edge approaches, including its industry-leading PEGylation technology platform used to create product candidates with benefits such as reduced dosing frequency and less toxicity. Enzon's PEGylation technology was used to develop two of its products, ONCASPAR and ADAGEN, and has created a royalty revenue stream from licensing partnerships for other products developed using the technology. Enzon also engages in contract manufacturing for several pharmaceutical companies to broaden the Company's revenue base.

Genmab A/S operates as an international biotechnology company. The firm develops human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline include daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998 and is headquartered in Copenhagen, Denmark.

Beijing Qiangxin Biotechnology Co., Ltd., established on 2011-12-07, Business scope includes biopharmaceutical technology research and development,technology transfer,Technical Services,technical consulting;Import and export,Technology Import and Export,Agent import and export.(Items subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments.)

BioInvent is a research-based pharmaceutical company developing innovative antibody drugs targeting cancers with unmet clinical need.Our drug development programmes are supported by our human antibody development platform. This consists of a proprietary antibody library, n-CoDeR:registered:, and in-house technology for the rapid selection, screening and identification of antibodies with excellent affinity and selectivity for targets. BioInvent has a high level of competence in antibody drug discovery, preclinical and clinical development. The Company also has many years' experience in process development and antibody manufacturing, which we carry out at our own facilities. Alongside our in house and partnered drug-development programmes we offer antibody discovery and development services to customers. BioInvent's business model and technology platform have been validated through numerous partnerships. These include a co-development agreement with Bayer, Daiichi Sankyo, Mitsubishi Tanabe, Servier and others. BioInvent employs around 50 people and is based in Lund, Sweden. The Company listed on the NASDAQ OMX Stockholm in 2001.

Senhwa Biosciences, Inc. engages in the research and development of anticancer drug and active pharmaceutical ingredient. It has two agents in clinical development for cancer, which includes CX-5461, a compound that activates p53 and kills cancer cells; and CX-4945, a compound that controls the growth and proliferation of cancer cells. The company was founded by Tai Sen Soong on November 16, 2012 and is headquartered in New Taipei, Taiwan.

AVEO is a late-stage biopharmaceutical company focused on the discovery and development of targeted cancer therapeutics. AVEO's proprietary, integrated cancer biology platform enables the company to pursue highly efficient drug development strategies in oncology that increase the probability of clinical success and provides a discovery engine for high-value targets and therapies. This approach has resulted in a balanced pipeline of novel cancer therapies focused on well-validated targets (VEGFR, EGFR) and promising novel targets (HGF, FGFR, ErbB3 and NOTCH), as well as collaborations with Eli Lilly, Merck, OSI Pharmaceuticals, Schering-Plough, and Biogen Idec. The company was established in 2001 and is based in Cambridge, Massachusetts.

Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer. Using a proprietary chemistry platform, Onconova has created an extensive library of targeted anti-cancer agents designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. It has three product candidates in clinical trials and six active pre-clinical programs. Onconova seeks to develop products that improve the outcome for cancer patients by directly addressing the disease, its recurrence, and the burden of side-effects associated with current methods of treatment.

Byondis BV is a biopharmaceutical firm. It develops antibody-drug conjugates, linker-drug platform, optimal therapeutic window, monoclonal antibodies, and pre-clinical research and development. The company was founded by Jacques Lemmens in 2007 and is headquartered in Nijmegen, the Netherlands.

Niiki Pharma is a development focused oncology company specializing in first-in-class cancer treatments directed at novel cellular targets and related companion diagnostics. With a team of experts in cancer drug development and commercialization, Niiki Pharma programs are characterized by quality, speed and capital efficient processes.

was founded in 2013 to develop novel compounds that are effective on both drug-resistant tumors and cancer stem cells. In numerous preclinical models of cancer, including colon, pancreatic, prostate, breast and lung cancers the company’s lead product SBT-1214 has shown to completely eliminate the tumor. Additional studies have shown that SBT-1214 is able to effectively down-regulate “stemness” gene expression and kill cancer stem cells. Additional chemical modifications and a novel fatty-acid based nanoemulsion formulation result in a drug that has improved pharmacokinetics and pharmacodynamics properties as well as reduced toxicity.

Canget BioTekpharma is a biotech and biopharma company used to develop novel, cancer-targeting anticancer agents. It provides low toxic and cancer-targeting anticancer agents for patients, enabling medical practitioners to improve patient survival time and survival rate through controlling cancer cell drug resistance and tumor relapse. The company focuses on the development of novel, cancer-targeting anticancer agents that exhibit low toxicity to normal tissue and high efficacy to cancer. Canget BioTekpharma was established in 2012 and is headquartered in Buffalo, New York.

ASLAN Pharmaceuticals Pte Ltd. develops novel medicines for global markets. It licenses preclinical and early clinical compounds from global pharmaceutical companies, focusing on oncology, respiratory and inflammation diseases and uses the high quality and efficient development resources available across Asia to progress the drugs through clinical development. The company was founded by Carl Aslan Jason Morton Firth, Mark McHale and Jeffrey Tomlinson in 2010 and is headquartered in Singapore.

Advanced Cardiovascular Systems, Inc. develops and manufactures cardiovascular medical products. It operates as a subsidiary of Abbott Laboratories. Its medical devices help patients with heart diseases in returning to active and productive lives and physicians for improving patient management and clinical outcomes. Advanced Cardiovascular Systems, Inc. is based in Santa Clara, California. it is currently known as Abbott Cardiovascular Systems.